Quince Therapeutics, Inc. (QNCX)
| Market Cap | 31.88M -62.9% |
| Revenue (ttm) | n/a |
| Net Income | -92.48M |
| EPS | -51.81 |
| Shares Out | 1.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,000 |
| Open | 32.79 |
| Previous Close | 31.00 |
| Day's Range | 30.50 - 32.99 |
| 52-Week Range | 15.10 - 909.98 |
| Beta | 1.31 |
| Analysts | Buy |
| Price Target | 75.17 (+139.78%) |
| Est. Earnings | Nov 11, 2026 |
About QNCX
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a dr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for QNCX stock is "Buy." The 12-month stock price target is $75.17, which is an increase of 139.78% from the latest price.
News
Quince Therapeutics upgraded to Outperform from Market Perform at Citizens
Citizens upgraded Quince Therapeutics (QNCX) to Outperform from Market Perform with a $77 price target following the reverse merger with Orphai Therapeutics. The company is developing LAM-001, a once-...
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modify...
Quince Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
LAM-001, an inhaled mTOR inhibitor, is advancing through clinical trials for BOS, PH-ILD, and SAPH, with strong KOL support and promising early data. Key readouts are expected in Q1 2027 for BOS and Q1 2028 for PH-ILD, targeting significant unmet needs in pulmonary diseases.
Quince Therapeutics to Participate in September 2026 Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modify...
Quince Therapeutics Proxy statement: Proxy filing
Quince Therapeutics filed a proxy statement on August 25, 2026, providing details for shareholder voting and corporate governance matters.
Craig-Hallum bullish on Quince Therapeutics, initiates with a Buy
As previously reported, Craig-Hallum initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $68 price target The firm notes Orphai, acquired by Quince earlier this year, is developing…
Quince Therapeutics initiated with a Buy at Craig-Hallum
Craig-Hallum initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $68 price target
Quince Therapeutics participates in a conference call with Cantor Fitzgerald
Analyst Schimmer holds a conference call with management.on August 17 at 1 pm hosted by Cantor Fitzgerald. Webcast Link
Quince Therapeutics reports Q2 EPS ($12.31), consensus ($12.39)
“This was a transformational quarter for the company with a renewed focus on a differentiated, late-stage pulmonary pipeline anchored by LAM-001 as well as a strengthened balance sheet to support…
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline
Quince Therapeutics Earnings release: Q2 2026
Quince Therapeutics released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Quince Therapeutics Quarterly report: Q2 2026
Quince Therapeutics has published its Q2 2026 quarterly earnings report on August 14, 2026.
Quince Therapeutics Registration statement: Registration filing
Quince Therapeutics filed a registration statement on August 5, 2026, providing details about a securities offering with the SEC.
Quince Therapeutics management to meet with Oppenheimer
Meeting to be held on August 10 hosted by Oppenheimer.
Quince Therapeutics registers to sell 15.47M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 15.47M shares of common stock. The company is not selling any…
Quince Therapeutics Registration statement: Registration filing
Quince Therapeutics filed a registration statement on July 31, 2026, providing details about a securities offering with the SEC.
Quince Therapeutics Proxy statement: Proxy filing
Quince Therapeutics filed a proxy statement on July 31, 2026, providing details for shareholder voting and corporate governance matters.
Quince Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mazahir Alimohamed initiated coverage of Quince Therapeutics (QNCX) with an Outperform rating and $82 price target The company’s LAM-001 is a once-daily inhaled mTOR inhibitor targ...
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifyi...
Quince Therapeutics trading halted, news pending
19:50 EDT Quince Therapeutics (QNCX) trading halted, news pending
Quince Therapeutics initiated with an Outperform at Leerink
Leerink analyst Joseph P. Schwartz initiated coverage of Quince Therapeutics (QNCX) with an Outperform rating and $4 price target Following its acquisition of Orphai Therapeutics, Quince has repositio...
Quince Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer Saunders initiated coverage of Quince Therapeutics (QNCX) with an Overweight rating and $4 price target The firm believes Quince offers one of the more compelli...
Quince Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Quince Therapeutics (QNCX) with an Overweight rating and $4 price target
UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor),...
Quince Therapeutics Transcript: Investor update
Announced the acquisition of Orphai and a $150M private placement to fund LAM-001, an inhaled rapamycin for multiple rare lung diseases. Phase II-A data in PH-ILD showed promising efficacy and safety, with key clinical milestones expected through 2028.